NRX Pharmaceuticals, Inc. Operating Expenses
NRX Pharmaceuticals, Inc. (NRXP) reported Operating Expenses of $3.73 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-08-18
- NRX Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-06-30 was $3.73M, a 47.09% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating expenses for the quarter ending 2024-12-31 was $2.43M, a 44.80% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating expenses for the quarter ending 2024-09-30 was $3.02M, a 47.97% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating expenses for the quarter ending 2024-06-30 was $7.05M, a 13.90% decline year-over-year.
- NRX Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $18.50M, a 33.53% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $27.84M, a 37.21% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $44.34M, a 61.71% decline from fiscal 2021.
- NRX Pharmaceuticals, Inc. operating expenses for fiscal 2021 was $115.80M, a 125.34% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $3.73M 10-Q · filed 2025-08-18 | $7.58M 10-Q · filed 2025-08-18 | ||||||
| 2024-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $5.45M derived: sum of 2 quarters · filed 2025-03-14 | $12.50M derived: sum of 3 quarters · filed 2025-08-18 | $18.50M 10-K · filed 2025-03-14 | ||||
| 2024-09-30 | $3.02M 10-Q · filed 2024-11-14 | $10.07M derived: sum of 2 quarters · filed 2025-08-18 | $16.07M 10-Q · filed 2024-11-14 | $20.48M derived: sum of 4 quarters · filed 2025-08-18 | ||||
| 2024-06-30 | $7.05M 10-Q · filed 2025-08-18 | $13.05M 10-Q · filed 2025-08-18 | $17.45M derived: sum of 3 quarters · filed 2025-08-18 | $23.26M derived: sum of 4 quarters · filed 2025-08-18 | ||||
| 2024-03-31 | $6.00M 10-Q · filed 2025-05-15 | $10.40M derived: sum of 2 quarters · filed 2025-05-15 | $16.21M derived: sum of 3 quarters · filed 2025-05-15 | $24.40M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $10.21M derived: sum of 2 quarters · filed 2025-03-14 | $18.40M derived: sum of 3 quarters · filed 2025-03-14 | $27.84M 10-K · filed 2025-03-14 | ||||
| 2023-09-30 | $5.81M 10-Q · filed 2024-11-14 | $14.00M derived: sum of 2 quarters · filed 2024-11-14 | $23.43M 10-Q · filed 2024-11-14 | $27.73M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-06-30 | $8.19M 10-Q · filed 2024-08-14 | $17.62M 10-Q · filed 2024-08-14 | $21.92M derived: sum of 3 quarters · filed 2025-05-15 | $31.06M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-03-31 | $3.85M 10-Q · filed 2025-05-15 | $9.44M 10-Q · filed 2023-05-15 | $13.73M derived: sum of 2 quarters · filed 2025-05-15 | $22.88M derived: sum of 3 quarters · filed 2025-05-15 | $32.48M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2022-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $19.03M derived: sum of 2 quarters · filed 2024-03-29 | $28.63M derived: sum of 3 quarters · filed 2024-03-29 | $44.34M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $9.14M 10-Q · filed 2023-11-14 | $18.74M derived: sum of 2 quarters · filed 2023-11-14 | $34.45M 10-Q · filed 2023-11-14 | $87.42M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $9.60M 10-Q · filed 2023-08-14 | $25.30M 10-Q · filed 2023-08-14 | $78.28M derived: sum of 3 quarters · filed 2023-08-14 | $98.38M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $15.71M 10-Q · filed 2023-05-15 | $68.68M derived: sum of 2 quarters · filed 2023-05-15 | $88.78M derived: sum of 3 quarters · filed 2023-05-15 | $105.90M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $52.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $73.07M derived: sum of 2 quarters · filed 2023-03-31 | $90.19M derived: sum of 3 quarters · filed 2023-03-31 | $115.80M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $20.10M 10-Q · filed 2022-11-14 | $20.10M 10-Q · filed 2021-11-15 | $37.22M derived: sum of 2 quarters · filed 2022-11-14 | $62.82M 10-Q · filed 2022-11-14 | $62.82M 10-Q · filed 2021-11-15 | $107.94M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $17.12M 10-Q · filed 2022-08-15 | $17.12M 10-Q · filed 2021-08-16 | $42.72M 10-Q · filed 2022-08-15 | $42.72M 10-Q · filed 2021-08-16 | $87.84M derived: sum of 3 quarters · filed 2022-08-15 | $92.99M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $25.61M 10-Q · filed 2022-05-16 | $235.58K 10-Q · filed 2021-05-21 | $70.73M derived: sum of 2 quarters · filed 2022-05-16 | $75.88M derived: sum of 3 quarters · filed 2022-08-12 | $75.77M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $45.12M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $50.27M derived: sum of 2 quarters · filed 2022-08-12 | $50.17M derived: sum of 3 quarters · filed 2022-08-12 | $51.39M 10-K · filed 2022-03-31 | $907.41K 10-K · filed 2021-04-01 | |||
| 2020-09-30 | $5.15M 10-Q/A · filed 2022-08-12 | $169.03K 10-Q · filed 2020-11-16 | $5.04M derived: sum of 2 quarters · filed 2022-08-12 | $6.26M 10-Q/A · filed 2022-08-12 | $469.59K 10-Q · filed 2020-11-16 | $5.35M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-06-30 | -$104.82K 10-Q/A · filed 2022-08-12 | $181.26K 10-Q · filed 2020-08-14 | $1.12M 10-Q/A · filed 2022-08-12 | $300.56K 10-Q · filed 2020-08-14 | $205.44K derived: sum of 3 quarters · filed 2022-08-12 | $388.75K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2020-03-31 | $119.30K 10-Q · filed 2021-05-21 | $310.26K derived: sum of 2 quarters · filed 2021-05-21 | $493.56K derived: sum of 3 quarters · filed 2021-05-21 | $669.31K derived: sum of 4 quarters · filed 2021-05-21 | ||||
| 2019-12-31 | $190.96K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $374.26K derived: sum of 2 quarters · filed 2021-05-14 | $550.01K derived: sum of 3 quarters · filed 2021-05-14 | $713.19K 10-K/A · filed 2021-05-14 | ||||
| 2019-09-30 | $183.31K 10-Q · filed 2020-11-16 | $359.05K derived: sum of 2 quarters · filed 2020-11-16 | $522.23K 10-Q · filed 2020-11-16 | $844.30K derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $175.74K 10-Q · filed 2020-08-14 | $338.92K 10-Q · filed 2020-08-14 | $661.00K derived: sum of 3 quarters · filed 2020-08-14 | $881.24K derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $163.18K 10-Q · filed 2020-05-15 | $485.26K derived: sum of 2 quarters · filed 2020-05-15 | $705.50K derived: sum of 3 quarters · filed 2020-05-15 | $977.31K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $322.08K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $542.32K derived: sum of 2 quarters · filed 2020-03-30 | $814.13K derived: sum of 3 quarters · filed 2020-03-30 | $1.01M 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | $220.24K 10-Q · filed 2019-11-14 | $492.05K derived: sum of 2 quarters · filed 2019-11-14 | $684.43K 10-Q · filed 2019-11-14 | $1.19K 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $271.81K 10-Q · filed 2019-08-14 | $464.18K 10-Q · filed 2019-08-14 | $598.66K derived: sum of 3 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | $192.37K 10-Q · filed 2019-05-15 | $326.85K derived: sum of 2 quarters · filed 2019-05-15 | ||||||
| 2017-12-31 | $134.48K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |